Gilead Strengthens HIV Growth Platform with Expanded Latin America Access

Gilead Strengthens HIV Growth Platform with Expanded Latin America Access

Fri, September 18, 2026 at 7:51 PM GMT+3 4 min read

• GILD -0.31%

Gilead Sciences, Inc. (NASDAQ:GILD) has reached an agreement with the Pan American Health Organization (PAHO) to expand access to its twice-yearly HIV-prevention drug lenacapavir across Latin America and the Caribbean. The agreement creates a regional procurement pathway through PAHO for 14 countries, including Brazil, Mexico, Argentina, Colombia and Peru, that were outside Gilead's existing voluntary generic-licensing arrangements.

Availability will still depend on individual countries' regulatory approvals and decisions to adopt the drug. Reuters notes that new HIV infections in Latin America and the Caribbean increased 13% between 2010 and 2024, highlighting a sizeable unmet prevention need. Gilead expects lenacapavir to generate about $1 billion in 2026 sales.

PAHO Deal Expands Lenacapavir's Growth Runway

The agreement could broaden lenacapavir's commercial footprint while strengthening the drug's position as Gilead Sciences, Inc. (NASDAQ:GILD)'s next major HIV growth driver. Gilead reported 12% year-over-year HIV sales growth in Q2 2026, while Yeztugo sales reached $232 million, above the $210 million analyst estimate, reinforcing management's confidence in achieving approximately $1 billion of full-year sales. Gilead subsequently raised its expected 2026 HIV-product sales growth to 9%-10%. The PAHO arrangement adds 14 markets to the access pathway and could provide a more coordinated route to government-funded procurement than country-by-country commercialization. That matters because Latin America has both rising HIV incidence and significant gaps in PrEP utilization.

The agreement also strengthens Gilead's competitive position around long-acting HIV prevention. Lenacapavir's twice-yearly dosing differentiates it from daily oral PrEP and can address adherence and supply-continuity problems associated with daily pills. Reuters reported that lenacapavir demonstrated nearly 100% efficacy in large prevention trials, while Gilead is simultaneously expanding the product into additional formulations and markets. The combination of U.S. commercial growth, international expansion, and additional licensing pathways therefore gives Gilead more opportunities to build a durable revenue stream around lenacapavir.

Local Production Could Further Constrain Commercial Returns

The principal financial limitation is that broader access does not necessarily translate into proportionate high-margin revenue. Gilead Sciences, Inc. (NASDAQ:GILD) has already granted royalty-free voluntary licenses to generic manufacturers for resource-limited countries, while its broader access strategy includes generic licensing, technology transfers, and partnerships. The PAHO pathway is specifically designed to improve regional access, meaning pricing and procurement terms could be materially lower than Gilead's commercial pricing in wealthier markets. This could constrain the revenue and margin contribution from Latin America even as patient reach expands.

There is also execution risk before the agreement becomes a meaningful earnings contributor. Country-level regulatory approvals, government adoption and procurement decisions remain necessary, and Gilead is still discussing possible local production with Brazil's Health Ministry. More broadly, Gilead Sciences, Inc. (NASDAQ:GILD)'s existing experience shows that expanding prevention access can involve substantial pricing pressure: Reuters reported that Yeztugo carries a U.S. annual list price above $28,000, while insurers have raised affordability concerns. The Latin American strategy therefore prioritizes volume and access, but the economic return per patient could be substantially below U.S. levels.

Conclusion

The PAHO agreement expands the addressable market for lenacapavir into 14 additional Latin American and Caribbean countries and supports Gilead Sciences, Inc. (NASDAQ:GILD)'s effort to make the drug a major HIV growth platform. The strongest financial evidence is already visible in the $232 million Q2 Yeztugo sales, 12% quarterly HIV-sales growth and the company's roughly $1 billion 2026 Yeztugo sales target.

However, royalty-free licensing, government procurement and potential local production mean greater regional access may come with lower pricing and margins. The development therefore strengthens the long-term growth opportunity for lenacapavir, while its near-term earnings impact will depend primarily on the pace of regulatory adoption, procurement volumes and pricing across individual markets.

While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on thebest short-term AI stock.

READ NEXT: Truist Reshapes Lending Strategy with $5.5B Auto-Loan Sale and JPMorgan Sees Investment Banking and Trading Powering Q3 Growth

This article is originally published at Insider Monkey.